Bias in Markov models of disease

Mathematical Biosciences

Volumn 220, Issue 2, 2009, Pages 143-156

  Faissol, Daniel M ^a   Griffin, Paul M ^a   Swann, Julie L ^a  

^a Georgia Institute of Technology   (United States)

Author keywords

Bias; Markov model; Monte Carlo simulation

Indexed keywords

ALZHEIMER'S DISEASE; BIAS; DATA AGGREGATION; DISEASE MODELS; DISEASE PROGRESSION; HEPATITIS C; INFECTIOUS DISEASE; LUNG CANCER; MARKOV MODEL; MEDICAL DATA; MONTE CARLO SIMULATION; SUFFICIENT CONDITIONS; TRANSITION PROBABILITIES;

MARKOV PROCESSES; MONTE CARLO METHODS; PROBABILITY;

SIMULATORS;

COMPUTER SIMULATION; DISEASE; MARKOV CHAIN; MONTE CARLO ANALYSIS; NUMERICAL MODEL;

ALZHEIMER DISEASE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; HEPATITIS C; LUNG CANCER; MATHEMATICAL COMPUTING; MONTE CARLO METHOD; PROBABILITY; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; STATISTICAL PARAMETERS; SYSTEMATIC ERROR;

AGE FACTORS; ALGORITHMS; ALZHEIMER DISEASE; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LUNG NEOPLASMS; MARKOV CHAINS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PROBABILITY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

HEPATITIS C VIRUS;

EID: 67650650463     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2009.05.005     Document Type: Article

References (49)

1. Sanders G.D., Bayoumi A.M., Sundaram V., Bilir S.P., Neukermans C.P., Rydzak C.E., Douglass L.R., Lazzeroni L.C., Holodniy M., and Owens D.K. Cost-effectiveness of screening for hiv in the era of highly active antiretroviral therapy. New England Journal of Medicine 352 6 (2005) 570
2. Paltiel A.D., Weinstein M.C., Kimmel A.D., Seage G.R., Losina E., Zhang H., Freedberg K.A., and Walensky R.P. Expanded screening for hiv in the united states - an analysis of cost-effectiveness. New England Journal of Medicine 352 6 (2005) 586
3. Barzilay E.J., O'Brien K.L., Kwok Y.S., Hoekstra R.M., Zell E.R., Reid R., Santosham M., Whitney C.G., and Feikin D.R. Could a single dose of pneurnococcal conjugate vaccine in children be effective? Modeling the optimal age of vaccination. Vaccine 24 7 (2006) 904
4. Alagoz O., Maillart L.M., Schaefer A.J., and Roberts M.S. The optimal timing of living-donor liver transplantation. Management Science 50 10 (2004) 1420
5. Alagoz O., Maillart L.M., Schaefer A.J., and Roberts M.S. Determining the acceptance of cadaveric livers using an implicit model of the waiting list. Operations Research 50 10 (2006) 1420
6. Wein L.M., Zenios S.A., and Nowak M.A. Dynamic multidrug therapies for hiv: a control theoretic approach. Journal of Theoretical Biology 185 1 (1997) 15
7. Wong J.B., McQuillan G.M., McHutchison J.G., and Poynard T. Estimating future hepatitis c morbidity mortality and costs in the united states. American Journal of Public Health 90 10 (2000) 1562
8. Armon C., Graves M.C., Moses D., Forte D.K., Sepulveda L., Darby S.M., and Smith R.A. Linear estimates of disease progression predict survival in patients with amyotrophic lateral sclerosis. Muscle and Nerve 23 6 (2000) 874
9. Ballard C., O'Brien J., Morris C.M., Barber R., Swann A., Neill D., and McKeith I. The progression of cognitive impairment in dementia with lewy bodies vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry 16 5 (2001) 499
10. Coreybloom J., Galasko D., Hofstetter C.R., Jackson J.E., and Thal L.J. Clinical-features distinguishing large cohorts with possible ad probable ad and mixed dementia. Journal of the American Geriatrics Society 41 1 (1993) 31
11. Farrer L.A., Cupples A., Vanduijn C.M., Connorlacke L., Kiely D.K., and Growdon J.H. Rate of progression of Alzheimers-disease is associated with genetic risk. Archives of Neurology 52 9 (1995) 918
12. Freeman A., Dore G., Law M., Thorpe M., Van Overbeck J., Lloyd A.R., Marinos G., and Kaldor J.M. Estimating progression to cirrhosis in chronic hepatitis c virus infection. Hepatology 34 4 (2001) 809
13. Hornberger J., Torriani F.J., Dieterich D.T., Brau N., Sulkowski M.S., Torres M.R., Green J., and Patel K. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. Journal Of Clinical Virology 36 4 (2006) 283
14. Kraemer H.C., Tinklenberg J., and Yesavage J.A. How far vs how fast in Alzheimers-disease - the question revisited. Archives of Neurology 51 3 (1994) 275
15. Salmon D.P., Thal L.J., Butters N., and Heindel W.C. Longitudinal evaluation of dementia of the Alzheimer type - a comparison of 3 standardized mental status examinations. Neurology 40 8 (1990) 1225
16. Singer M.E., and Younossi Z.M. Cost effectiveness of screening for hepatitis c virus in asymptomatic average-risk adults. American Journal of Medicine 111 8 (2001) 614
17. H.E. Kirkizlar, D. Faissol, P. Griffin, J. Swann, Timing of testing and treatment for asymptomatic diseases, Working paper, Georgia Institute of Technology.
18. C. Scherrer, The allocation of scarce resources in public health, Ph.D. Thesis, Georgia Institute of Technology, 2005.
19. Commentary: Fine-tuning Life-espectancy Calculations Using Markov Processes: To the Editor, Med Decis Making 13 (2) (1993) 170. Available from: .
20. Davis B.A., Heathcote C.R., and O'neill T.J. Estimating and interpolating a Markov chain from aggregate data. Biometrika 89 1 (2002) 95-110
21. Yi Q., Wang P.P., and Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis c virus infection. Journal of Viral Hepatitis 11 2 (2004) 166-174
22. G. Kotsalis, M. Dahleh, Model reduction of irreducible Markov chains, in: Decision and Control, Proceedings of 42nd IEEE Conference, 2003. vol. 6, pp. 5727-5728.
23. G. Kotsalis, A. Megretski, M. Dahleh, A model reduction algorithm for hidden markov models, in: Decision and Control, Proceedings of 45th IEEE Conference, 2006. vol. 6, pp. 3424-3429.
24. Marek I. Iterative aggregation/disaggregation methods for computing some characteristics of Markov chains. II Fast convergence. Applied Numerical Mathematics 45 1 (2003) 11
25. M. Vidyasagar, Bounds on the Kullback-Leibler divergence rate between hidden markov models, in: Decision and Control, 46th IEEE Conference, 2007, pp. 6160-6165. http://dx.doi.org/10.1109/CDC.2007.4434365.
26. Rached Z., Alajaji F., and Campbell L.L. The Kullback-Leibler divergence rate between Markov sources. Information Theory IEEE Transactions 50 5 (2004) 917. http://dx.doi.org/10.1109/TIT.2004.826687 http://dx.doi.org/10.1109/TIT.2004.826687
27. Salomon J.A., and Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis c infection - reply. Jama-Journal Of The American Medical Association 290 15 (2003) 1994
28. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis c. Lancet 349 9055 (1997) 825
29. Zarski J.P., Mc Hutchison J., Bronowicki J.P., Sturm N., Garcia-Kennedy R., Hodaj E., Truta B., Wright T., and Gish R. Rate of natural disease progression in patients with chronic hepatitis c. Journal of Hepatology 38 3 (2003) 307
30. Bennett W.G., Inoue Y., Beck J.R., Wong J.B., Pauker S.G., and Davis G.L. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine 127 10 (1997) 918
31. Matsumura H., Moriyama M., Goto I., Tanaka N., Okubo H., and Arakawa Y. Natural course of progression of liver fibrosis in japanese patients with chronic liver disease type c - a study of 527 patients at one establishment. Journal of Viral Hepatitis 7 4 (2000) 268
32. Poynard T., Ratziu V., Charlotte F., Goodman Z., McHutchison J., and Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. Journal of Hepatology 34 5 (2001) 730
33. Silini E.M., Cavallero A., Dal Bello B., Bruno R., Barbarini G., Belloni G., Cividini A., Tinelli C., and Mondelli M.U. Modelling liver fibrosis progression in chronic hepatitis c: a study of 563 patients with sequential liver biopsies. Journal of Hepatology 44 (2006) S36 Silini, E.M. Cavallero, A. Dal Bello, B. Bruno, R. Barbarini, G. Belloni, G. Cividini, A. Tinelli, C. Mondelli, M.U. Suppl. 2
34. Jonsson L., Lindgren P., Wimo A., Jonsson B., and Winblad B. The cost-effectiveness of donepezil therapy in swedish patients with Alzheimer's disease: a Markov model. Clinical Therapeutics 21 7 (1999) 1230
35. Galasko D., Coreybloom J., and Thal L.J. Monitoring progression in Alzheimers-disease. Journal of the American Geriatrics Society 39 9 (1991) 932
36. Stern R.G., Mohs R.C., Davidson M., Schmeidler J., Silverman J., Kramerginsberg E., Searcey T., Bierer L., and Davis K.L. A longitudinal-study of Alzheimers-disease - measurement rate and predictors of cognitive deterioration. American Journal of Psychiatry 151 3 (1994) 390
37. Suh G.H., Ju Y.S., Yeon B.K., and Shah A. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline. International Journal of Geriatric Psychiatry 19 9 (2004) 817
38. Stewart A., Phillips R., and Dempsey G. Pharmacotherapy for people with alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. International Journal of Geriatric Psychiatry 13 7 (1998) 445
39. Tavakoli M., and Malek M. The cost utility analysis of riluzole for the treatment of amyotrophic lateral sclerosis in the UK. Journal of the Neurological Sciences 191 1-2 (2001) 95
40. Plunkett B.A., and Grobman W.A. Routine hepatitis c virus screening in pregnancy: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 192 4 (2005) 1153
41. Tanaka J., Kumada H., Ikeda K., Chayama K., Mizui M., Hino K., Katayama K., Kumagai J., Komiya Y., Miyakawa Y., and Yoshizawa H. Natural histories of hepatitis c virus infection in men and women simulated by the markov model. Journal of Medical Virology 70 3 (2003) 378
42. Stein K., Dalziel K., Walker A., Jenkins B., Round A., and Royle P. Screening for hepatitis c in genito-urinary medicine clinics: a cost utility analysis. Journal of Hepatology 39 5 (2003) 814
43. Petersen R.C., Stevens J.C., Ganguli M., Tangalos E.G., Cummings J.L., and DeKosky S.T. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) - report of the quality standards subcommittee of the American academy of Neurology. Neurology 56 9 (2001) 1133
44. United States Department of Health and Human Services, The health consequences of smoking: a report of the surgeon general. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
45. Ross S. Stochastic Processes (1995), Wiley, New York
46. Centers for Disease Control and Prevention, Deaths: Final data for 2003, National Vital Statistics Reports 54 (13). Available from: , Accessed December 2006.
47. Doll R., and Peto R. Cigarette-smoking and bronchial-carcinoma - dose and time relationships among regular smokers and lifelong non-smokers. Journal of Epidemiology and Community Health 32 4 (1978) 303
48. Park H.L., O'Connell J.E., and Thomson R.G. A systematic review of cognitive decline in the general elderly population. International Journal of Geriatric Psychiatry 18 12 (2003) 1121
49. Aguero-Torres H., Fratiglioni L., and Winblad B. Natural history of Alzheimer's disease and other dementias: review of the literature in the light of the findings from the Kungsholmen project. International Journal of Geriatric Psychiatry 13 11 (1998) 755